Table 3 Application of CVVH in patients with IAH
| Â | CVVH N= 60 | No CVVH N= 29 | p | |
|---|---|---|---|---|
Demographics | Age, years | 45.1 ± 13.4 | 51.3 ± 16.4 | NS |
| Â | Male, n (%) | 52 (86.7%) | 18 (62.1%) | Â |
| Â | Time from the first symptom to hospitalization, median hours (IQR) | 32 (60 to 12) | 24 (34 to 4) | NS |
|  | APACHE II at admission, points | 7.9 ± 5.1 | 7.2 ± 4.2 | NS |
|  | IAP on admission, mmHg | 15.4 ± 3.7 | 14.5 ± 3.7 | NS |
|  | SOFA on admission, points | 2.4 ± 2.2 | 2.0 ± 1.9 | NS |
| Â | Necrotizing SAP, n (%) | 49 (81.7%) | 16 (55.2%) | 0.01 |
| Â | MODS, n (%) | 58 (96.7%) | 26% (89.7) | NS |
| Â | ACS, n (%) | 23 (38.3%) | 10 (34.5%) | NS |
Organ dysfunctions | Renal, n (%) | 27 (45%) | 8 (27.6%) | NS |
| Â | Pulmonary, n (%) | 11 (18.3%) | 3 (10.3%) | NS |
| Â | Liver, n (%) | 6 (10%) | 3 (10.3%) | NS |
| Â | Cardiovascular, n (%) | 5 (8.3%) | 2 (6.9%) | NS |
| Â | Hematologic, n (%) | 4 (6.7%) | 3 (10.3%) | NS |
| Â | Neurologic, n (%) | 15 (25%) | 4 (13.8%) | NS |
Complications | Metabolic acidosis, n (%) | 15 (25%) | 2 (6.9%) | 0.05 |
| Â | Pleural effusion, n (%) | 40 (66.7%) | 11 (37.9%) | 0.01 |
| Â | Pneumonia, n (%) | 28 (46.7%) | 4 (13.8%) | 0.002 |
| Â | Atelectasis, n (%) | 8 (13.3%) | 2 (6.9%) | NS |
| Â | Pancreatic/peripancreatic infection, n (%) | 16 (26.7%) | 11 (37.9%) | NS |
| Â | Surgical intervention, n (%) | 16 (26.7%) | 10 (34.5%) | NS |